Company intelligence / Profile preview

Panbela Therapeutics

Waconia, Minnesota, United Statespanbela.com ↗

Ownership: Public · PBLA
Employees: ~8
Development stage: Other

Overview

Panbela’s lead asset ivospemin (SBP‑101) has shown promising results in clinical studies for metastatic pancreatic ductal adenocarcinoma with a median overall survival of 14.6 months and an objective response rate of 48%, both exceeding typical outcomes for standard-of-care regimens. The ongoing global Phase III ASPIRE trial continues after three positive safety reviews by the DSMB. Flynpovi™ for FAP has completed pivotal trials and additional indications are being explored across their pipeline.

Therapeutic areas: GastroenterologyOncologyEndocrinology
Modalities: small molecules (notably polyamine analogues and metabolic inhibitors)
Industry: Biotech

Drug pipeline

2 assets

ivospemin

1 more asset in the full pipeline.

Partnerships

Johns Hopkins University School of Medicine research agreement for development of ivospemin/SBP‑101Clinical collaborations with Moffitt Cancer Center on STK11 mutant NSCLC programFunding partnership with Nant Capital LLC ($12 million investment)

Financials

Market cap: $53.9K
Total revenue: $0
Enterprise value: $6.3M

Beyond the preview

Go deeper on Panbela Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Panbela Therapeutics.